Skip to main content
Premium Trial:

Request an Annual Quote

Report Predicts Impact on Industry of Evolving Pharmacogenetics Technologies


WALTHAM, Mass.--Pharmacogenetics technology will have huge consequences for drug discovery and development efforts, according to a new market analysis report by Decision Resources, a healthcare research and consulting firm here. The inception of pharmacogenetics--a term the report interchanges with pharmacogenomics--is an outgrowth of the inversion of the drug-discovery paradigm brought about by genomics, the consulting firm reported. Molecular characterization of genes used to stratify patient populations and design diagnostics and therapeutics has led to the emergence of pharmacogenetics, the report said.

Pharmacogenetics is defined by Decision Resources as the study of the linkage between patients' genotypes and their ability to metabolize a foreign compound. Pharmacogenetics facilitates the stratification of patients suffering from a given disease by the genetic lesions involved in the molecular disease process, it explained. The discipline seeks to divide up a patient population base into its true components, each defined by a single genetic lesion and each able to be therapeutically targeted differentially.

Genomics and pharmaceutical companies are racing to develop technologies that will help researchers determine exactly how different individuals or subpopulations will respond to drugs, the report said. Companies such as DiaDexus and Millennium Predictive Medicine were created exploit this opportunity, the report pointed out.

It predicted pharmacogenetics will have significant consequences for drug development by making it easier for pharmaceutical companies to demonstrate drug efficacy and thereby reduce time to market; by enabling drug developers to predict adverse responses to certain drugs and reduce the costs of therapeutic failures; and by allowing drugs that have failed clinical trials because of efficacy or toxicity problems to be rescued.

The full report, "Personalized Medicine: The Impact of Pharmacogenetics on Drug Development," includes a valuation of the genomics and pharmacogenetics markets. For further information, contact Decision Resources at (781) 487-3737.

Filed under

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk off venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.